FDA clears Fujifilm Sonosite POCUS for COVID-19 use

2020 02 05 19 22 7323 Fujifilm Rsna 2019 400

Ultrasound developer Fujifilm SonoSite has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the use of its point-of-care ultrasound (POCUS) for performing lung and cardiac imaging of COVID-19 patients.

In announcing the clearance, Fujifilm Sonosite notes that POCUS has emerged as a portable, efficient tool for examining patients suspected of having COVID-19 at the point of care. The 510(k) clearance applies to the company's entire POCUS portfolio.

In conjunction with the FDA's move, the company released a user guide to help healthcare providers in how to best use POCUS to interpret ultrasound images to recognize the most common COVID-19 findings with respect to lung and cardiac conditions.

Page 1 of 507
Next Page